Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
« Hide
More detailed introduction
Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the NC-IUPHAR Subcommittee on Somatostatin Receptors [9]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28 (SRIF-28 (SST, P61278)). Cortistatin-14 has also been suggested to be an endogenous ligand for somatostatin receptors [5].
SST1 receptor
C
Show summary »
More detailed page |
SST2 receptor
C
Show summary »
More detailed page |
SST3 receptor
C
Show summary »
More detailed page |
SST4 receptor
C
Show summary »
More detailed page |
SST5 receptor
C
Show summary »
More detailed page |
Database page citation:
Stefan Schulz, Corinne Bosquet, Justo Castano, Micheal Culler, Jacques Epelbaum, Wasyl Feniuk, Anthony Harmar, Rebecca Hills, Leo Hofland, Daniel Hoyer, Patrick P. A. Humphrey, Wolfgang Meyerhof, Anne-Marie O'Carroll, Yogesh C. Patel, Terry Reisine, Jean-Claude Reubi, Marcus Schindler, Herbert Schmid, Agnes Schonbrunn, John E. Taylor, Annamaria Vezzani. Somatostatin receptors. Accessed on 20/02/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2017) The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 174 Suppl 1: S17-S129.
[125I]Tyr11-SRIF-14, [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr10-CST14 may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype-selective agonists have been synthesised [17]. Octreotide and lanreotide are being used in the treatment of SST2-expressing neuroendocrine tumors and pasireotide for SST5-expressing neuroendocrine tumors. A novel peptide somatostatin analogue, veldoreotide (COR-005), has affinity for SST2, SST4 and SST5 receptors and is a potent inhibitor of GH secretion [16,19].